Ann: CAN-003 INTERIM ANALYSIS PRESENTATION , page-5

So you consider the data has no more relevance that what was known in 2002. Sorry, boiler but I cannot agree with such a statement. The ICS and PFS data is in the form of a scientific study that is progressing through the various stages to satisfy the powers to be as to the efficacy and safety of CVac as a treatment for ovarian cancer. It is the building blocks for coming to a final conclusion. Far different than statements made in 2002.

The market is basically churn by traders. The great bulk of shareholders are sitting it out awaiting the continued progression of trial data. Based on the results the market will eventually determine what will be considered a sustainable price for the shares. In the meantime its a typical pattern of trading going on in no great volumes. For long term holders , that imo comprises most of the share register, their key interest is the continued positivity of the trial data as it accumulates over time.

If each batch of interim data widens the gap in terms of cancer recurrence between the control group and the CVac group the sp will sort itself out.

In the meantime we put up with the ongoing typical market machinations mainly by those attempting to make a quick buck, such as yourself lol.